Literature DB >> 21161640

[Insulin based combination treatments of patients with obesity and type 2 diabetes].

M Schütt1.   

Abstract

Besides classical antidiabetic goals the contemporary diabetology more intensely focuses on the reduction of cardiovascular risk factors of type 2 diabetic patients. Especially, potentially deleterious consequences of insulin therapies are debated, since avoiding hypoglycemic events and the possibility of weight loss represent advantageous cardiovascular effects of an antidiabetic therapy. On the other hand, a large proportion of patients receive insulin treatment during progression of the disease. In order to improve the cardiovascular risk profile of these patients, the combination of insulin with additional oral antidiabetic treatment should be considered. Positive effects are yielded, if the combination allows an optimized glucose control without an increase of hypoglycemic events or weight gain, or if the insulin dose and the body weight can be reduced. Options of such insulin based combination treatments and their potential cardiovascular impact are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21161640     DOI: 10.1007/s00108-010-2776-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  Adipocytes as regulators of energy balance and glucose homeostasis.

Authors:  Evan D Rosen; Bruce M Spiegelman
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

2.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood
Journal:  Eur Heart J       Date:  2007-01       Impact factor: 29.983

3.  UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors.

Authors: 
Journal:  Diabetes Res       Date:  1990-01

Review 4.  Insulin feedback action on pancreatic beta-cell function.

Authors:  Ingo B Leibiger; Barbara Leibiger; Per-Olof Berggren
Journal:  FEBS Lett       Date:  2002-12-04       Impact factor: 4.124

Review 5.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Authors:  Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati
Journal:  Arch Intern Med       Date:  2008-10-27

6.  Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.

Authors:  O Schnell; G Mertes; E Standl
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

7.  Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.

Authors:  M L Shank; S Del Prato; R A DeFronzo
Journal:  Diabetes       Date:  1995-02       Impact factor: 9.461

8.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.

Authors:  Frank B Hu; Meir J Stampfer; Steven M Haffner; Caren G Solomon; Walter C Willett; JoAnn E Manson
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

Review 9.  Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.

Authors:  Christine Clar; Pamela Royle; Norman Waugh
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

10.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Authors:  Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott
Journal:  BMJ       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.